Merck splits human health business into separate oncology and non-cancer units
The drugmaker is dividing its human health business into two units to prepare for the patent loss of Keytruda. One division will focus on oncology drugs.
Insights:
Merck & Co., Inc. announced on February 23, 2026, that it will separate its human-health business into two divisions as a corporate reorganization intended to offset pressures related to the patent loss of its top-selling drug Keytruda. This strategic move, which has been reported by the Wall Street Journal, is designed to address the operational and commercial impact associated with the loss of patent protection for the oncology treatment.
